Status:

COMPLETED

Incidence and Outcomes Associated With the Management of Adenovirus Infections in Allogenic Hematopoietic Cell Transplant Recipients

Lead Sponsor:

Jazz Pharmaceuticals

Conditions:

Adenovirus Infections, Human

Eligibility:

All Genders

Up to 90 years

Brief Summary

To depict the incidence, outcomes and standards of care (SoC) of adenovirus (AdV) infections and associated practice patterns in allogeneic hematopoietic cell transplant recipients. It is expected tha...

Eligibility Criteria

Inclusion

  • At least one AdV positive test, regardless of specimen within 6 months following the first allo-HCT
  • Subjects first allo-HCT must have been performed between 1 January 2013 and 30 September 2015

Exclusion

  • AdV negative

Key Trial Info

Start Date :

January 1 2013

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

January 1 2017

Estimated Enrollment :

216 Patients enrolled

Trial Details

Trial ID

NCT04285788

Start Date

January 1 2013

End Date

January 1 2017

Last Update

March 25 2022

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Incidence and Outcomes Associated With the Management of Adenovirus Infections in Allogenic Hematopoietic Cell Transplant Recipients | DecenTrialz